The present experiments were undertaken to examine the hypothesis that glucose-induced increased de novo synthesis of 1,2-diacyl-sn-glycerol (which has been observed in a number of different tissues, including retinal capillary endothelial cells exposed to elevated glucose levels in vitro) and associated activation of protein kinase C may play a role in mediating glucoseinduced vascular functional changes. We report here that twice daily instillation of 30 mM glucose over 10 -d in a rat skin chamber granulation tissue model induces approximately a 2.7-fold increase in diacylglycerol (DAG) levels (versus tissues exposed to 5 mM glucose) in association with marked increases in vascular clearance of albumin and blood flow. The glucose-induced increase in DAG levels as well as the vascular functional changes are prevented by addition of 3 mM pyruvate. Pharmacological activation of protein kinase C with the phorbol ester TPA in the presence of 5 mM glucose increases microvascular albumin clearance and blood flow, and similar effects are observed with 1-monoolein (MOG), a pharmacological inhibitor of the catabolism of endogenous DAG. A pharmacological inhibitor of protein kinase C (staurosporine) greatly attenuates the rise in microvascular albumin clearance (but not the rise in blood flow) induced by glucose or by MOG. These findings are compatible with the hypothesis that elevated concentrations of glucose increase tissue DAG content via de novo synthesis, resuIting in protein kinase C activation, and that these biochemical events are among the factors that generate the increased microvascular albumin clearance. (J. Clin. Invest. 1991.
Introduction
Vascular functional changes induced by elevated glucose levels are strongly linked to increased flux of glucose via the sorbitol pathway (1) (2) (3) (4) . However, the nature ofthe sorbitol-linked metabolic imbalance(s) which mediate these vascular changes remains unclear (2, 5) . Elevation of glucose levels has recently been demonstrated to stimulate de novo synthesis of 1,2-diac-Receivedfor publication 22 February 1990 and in revisedform 4 September 1990.
yl-sn-glycerol (DAG)' in a variety of tissues including vascular cells (6) (7) (8) (9) (10) . Based on evidence linking glucose-induced activation of protein kinase C to increased de novo synthesis ofDAG in retinal capillary endothelial cells in vitro, coupled with the pleiotropic effects of protein kinase C and DAG on cellular functions (1 1), Lee et al. (12) have postulated that increased de novo synthesis of DAG and associated activation of protein kinase C might play an important role in initiating vascular complications of diabetes. Indeed elevated DAG levels have been reported in the heart, retina, and kidney of diabetic rats (13) (14) (15) , and protein kinase C activation has been demonstrated in retina and in glomeruli of diabetic rats as well as in retinal capillary endothelial cells exposed to elevated glucose levels in vitro (13, 14) . Williamson et al. have recently described a model in which the microvascular abnormalities induced by elevated glucose concentrations can be examined in skin chamber granulation tissue (16) . The microvasculature in such chambers into which 11-30 mM D-glucose has been instilled over several days exhibits two distinct functional changes: increased albumin clearance and increased blood flow (16) . These vascular changes are similar to those exhibited by granulation tissue microvasculature from streptozotocin-diabetic rats (4, 17) . In the present study we have examined (a) whether the glucose-induced functional abnormalities in this model are associated with glucoseinduced DAG accumulation in skin chamber granulation tissue, (b) whether these microvascular functional abnormalities can be prevented by a pharmacological inhibitor of protein kinase C, and (c) whether the functional abnormalities can be induced at physiological glucose levels by exogenous activators ofprotein kinase C or by inhibitors ofthe catabolism ofendogenous DAG. 
Methods

Materials
Skin chamber insertion
A modification of the granulation tissue-skin chamber model utilized by Lundberg and Gerdin (18) was employed for these studies (16) . In brief, 2-cm circles ofskin were removed from the back on either side of the midline (after shaving the hair) ofnormal nondiabetic rats anesthetized with sodium pentobarbital (35 mg/kg) injected intraperitoneally. The flanged base ofthe plastic chamber was then sutured to the skin at the margins of the wound with the skin overlapping the flange to prevent reepithelialization of the granulation tissue inside the chamber and separation ofthe chamber from the skin by regrowth of hair. New vessels and granulation tissue then form spontaneously on the surface of the exposed fascia inside the chamber. The chambers are equipped with stainless steel screwcaps which are readily removed to permit addition of pharmacological agents to the new vessels as they form inside the chamber. Rats had unlimited access to water and rodent chow throughout the experiment.
Protocolfor topical application ofreagents to granulation tissue 10 (or 18) d after insertion of the chambers, 1.5 ml of Hepes buffer (25 mM Hepes pH 7.4,137 mM NaCl, 4.2 mM KCI, 3 mM Na2HPO4, 100
Ag/ml penicillin G, 10 Mg/mlgentamicin, 2% polyvinylpyrolidone) supplemented with one or more of the following reagents was added to each chamber: (a) 5 or 30 mM 1-glucose; (b) I or 10 M TPA, which is a phorbol ester activator of protein kinase C; (c) I or 5 MM staurosporine, which is an inhibitor of protein kinase C; (d) 100 or 700 AM monoolein, which is an inhibitor of DAG kinase; (e) 3 mM pyruvate; () 200 or 625 MM l-oleoyl-2-acetyl-sn-glycerol, which is a membranepermeable analogue of DAG; or (g) 700 MM oleic acid. Solutions were prepared fresh daily from stock solutions. The vehicle DMSO (0.05%) was present in each condition. These solutions were added twice daily (9:00 AM and 5:00 PM) for 2 d or for 10 d to the chambers. Within an hour of the last treatment, albumin clearance and blood flow were assessed and granulation tissue was removed for quantification of DAG levels.
Measurement of albumin clearance and blood flow of granulation tissue Animal preparation. After 10 d of topical application of the reagents described above, rats were anesthetized with thiopental (Squibb) (50 mg/kg body weight given intraperitoneally) and the left femoral vein and both iliac arteries were cannulated with polyethylene tubing filled with heparinized saline. The femoral vein cannula was used for tracer injection. The right iliac artery cannula was connected to a Statham P50 pressure transducer for monitoring blood pressure as well as for arterial blood sampling, and the left iliac artery cannula was connected to a withdrawal pump for assessment of regional blood flow. The trachea also was Blood flow (expressed as milliliters blood -gram wet weight-' i min-') was measured by injecting 15 Mzm 85Sr-microspheres (NEN Research Products) as described in previous publications (20, 21) .
Measurement ofDAG content ofgranulation tissue
Extraction of DAG from granulation tissue. Granulation tissue was stored at -70'C (< 72 h) until extraction. Frozen granulation tissue was pulverized in a percussion mill on dry ice. The powdered tissue was transferred to a silanized 16 X 100 borosilicate tube. Internal standard (100,000-200,000 dpm of l-stearoyl-2-[3H8]-arachidonyl-sn-glycerol) was added to each tube. Each tube then received H20 (0.5 ml) and chloroform/methanol (4.5 ml of a 1:2 solution (vol/vol) with 0.05% butylated hydroxytoluene). Tubes were then sonicated 60 min in a water bath and vortexed I min. Water (2 ml) was then added. The tubes were vortexed (I min) and then centrifuged (5 min at 900 g). The lower organic phase was transferred to a silanized 10 ml disposable borosilicate conical tube. The aqueous phase was reextracted with chloroform/ methanol (2 ml), chloroform (I ml), and water (2 ml), and was centrifuged. The lower (organic) phase was combined with that from the first extraction. The organic phase was washed with water (I ml), and the aqueous phase was saved for determination of its protein content. The organic phase was evaporated under N2, reconstituted with chloroform/methanol (0.5 ml), evaporated again, and then reconstituted in 0.05 ml of chloroform.
Enzymatic measurement ofDAG mass. DAG mass was measured by an enzymatic assay employing diacylglycerol kinase from E. coli to phosphorylate DAG to [32Plphosphatidic acid which was then quantitated as previously described (22) with modifications as specified elsewhere (10) . We have previously shown that under our conditions the modified assay is linear from 100 pmol to the low nanomolar range (10) . Furthermore, the mass of DAG measured by this modified enzymatic assay shows an excellent correspondence with the mass of DAG measured by gas chromatographic-negative ion-chemical ionizationmass spectrometric determination of its fatty acyl content (23 
Statistical analysis
Results are shown as mean±SE and were analyzed either by one-way or two-way ANOVA: albumin clearance, blood flow, and DAG content were considered the dependent variables in the ANOVA while the various treatments were independent variables. If the ANOVA indicated the presence of a statistically significant effect of treatment (P < 0.05), differences between the means within the treatment group were analyzed by a two-tailed t test using the residual variance estimate from the ANOVA: a P < 0.05 was considered statistically significant.
Results
Effect ofelevatedglucose concentrations on microvascular albumin clearance and bloodflow and on the DAG content ofgranu- (Fig. 1 C) . Pyruvate also totally prevented the glucose-induced rise in microvascular albumin clearance after 10 d (Fig. 1 A) but blocked the rise in blood flow by only 50% (Fig. 1 B) . These observations suggested that the rise in DAG content induced by glucose over 10 d might be functionally connected to the glucose-induced increment in microvascular albumin clearance, possibly via activation of protein kinase C. This possibility was further examined with pharmacological modulators of protein kinase C activity. Effects ofpharmacological activation ofprotein kinase C at physiological glucose concentrations on microvascular albumin clearance and blood flow in granulation tissue. The phorbol ester TPA is a recognized activator of protein kinase C and binds at the DAG site on the enzyme (1 1). As illustrated in Fig.  2 , when coadministered with a physiological concentration (5 mM) of 1-glucose, TPA (10 MM) was found to induce a rise in microvascular albumin clearance to a value nearly as great as that achieved with 30 mM glucose alone and significantly greater than that achieved by 5 mM glucose alone (Fig. 2 A) .
TPA (10 gM) also induced a rise in blood flow in the skin chamber granulation tissue to a value roughly half as great as that achieved by 30 mM glucose alone but still significantly greater than that of 5 mM glucose alone (Fig. 2 B) . TPA did not influence the DAG content of granulation tissue (ratio of 1.23±0.41 compared to 5 mM glucose control). Granulation tissue formation was induced in bilateral skin chambers in nondiabetic male rats as described in the legend of At a concentration of 1 MM, TPA exerted relatively little influence on microvascular permeability to albumin, although it did increase blood flow significantly to a level -50% ofthat induced by 30 mM glucose (Fig. 2 A) . Similarly, 1 MM TPA did not influence the cytosolic to membrane distribution ofprotein kinase C enzymatic activity in granulation tissue, as illustrated in Fig. 3 , although 10 MM TPA did induce the translocation of protein kinase C enzymatic activity from cytosol to membrane. Thus, the increase in microvascular albumin permeability and the translocation of protein kinase C exhibit similar relationships to the concentration of TPA. These observations indicated that pharmacological activation ofprotein kinase C mimicked almost completely the effect of elevated glucose concentrations on microvascular albumin clearance and partially reproduced the effect on blood flow. This is consistent with a role for protein kinase C activation in mediating some effects of glucose on microvascular functional parameters.
The fact that glucose itself did not induce demonstrable translocation of protein kinase C activity in granulation tissue (Fig. 3) Figure 2 . Effect of TPA, a protein kinase C activator, on albumin clearance and blood flow in granulation tissue from skin chambers exposed to 5 mM D-glucose. Granulation tissue formation was induced as described in Fig. I and Methods. Granulation tissue in skin chambers received twice daily 1. (26, 27) . As illustrated in Fig. 4 , staurosporine (5 4M) did not significantly influence microvascular albumin clearance (Fig. 4 A) or blood flow (Fig. 4 B) 4 A, P = 0.0012). These observations are consistent with the hypothesis that activation of protein kinase C mediates the increase in microvascular albumin clearance induced by glucose. This activation may be effected by the glucose-induced rise in endogenous DAG demonstrated in Fig. 1 C. This possibility was further explored with a pharmacological inhibitor of the catabolism of endogenous DAG.
Effects of a pharmacological inhibitor of DAG kinase on microvascular albumin clearance and blood flow. The compound I -mono-oleoyl-sn-glycerol (MOG) is an inhibitor ofthe enzyme (DAG kinase) which converts DAG to phosphatidic acid (28 FigureS. Effect of monoolein, an inhibitor of DAG metabolism, on albumin clearance and blood flow in granulation tissue from skin chambers exposed to 5 mM 1)-glucose. Granulation tissue formation was induced as described in Fig. 1 impair the catabolism ofendogenous DAG and to augment its accumulation (23, 28) . As illustrated in Fig. 5 A, when coadministered with a physiological concentration (5 mM) of glucose, MOG induced a substantial rise in microvascular albumin clearance to a value two-thirds ofthat achieved by 30 mM glucose and nearly threefold higher than that observed with instillation of 5 mM glucose alone. The MOG-induced rise in albumin clearance was essentially completely prevented by the protein kinase C inhibitor staurosporine, which is compatible with the hypothesis that the effect of MOG is mediated by accumulation of endogenous DAG and activation of protein kinase C. As illustrated in Fig. 5 B, MOG also induced a rise in blood flow when coadministered with 5 mM glucose to a value essentially identical to that achieved by 30 mM glucose. The effect of MOG to increase blood flow was little affected by staurosporine, however, indicating that this event may be independent of protein kinase C activation. The DAG content of granulation tissue was not demonstrably altered by MOG (ratio 1.17±0.13 compared to 5 mM glucose control) at the time of assay, although transient elevation of DAG causing sustained activation of protein kinase C cannot be excluded. Neither oleic acid (700 MAM) nor I-oleoyl-2-acetyl-sn-glycerol (200 MAM or 625 gM) mimicked the effects of MOG on albumin clearance or blood flow (not shown).
Sorbitol and myo-inositol content ofgranulation tissue. The sorbitol and myo-inositol contents of granulation tissue from skin chambers exposed to various treatments are shown in Table II. Myo-inositol content was not affected by any of the (8) 4.5±2.6t 563±147 +5 ,M staurosporine (6) 2.0± 1.4 49 1±90 +700 MM monoolein (6) 2.4 ± 2.0 476±76 +700 MM monoolein + 5 gM staurosporine (7) 2.3±1.7 480±65 +700 MAM oleic acid (4) 2.3±1.5 523±77 +625 ,M OAG (2) 7.4+3.9* 586±31 30 mM glucose (6) 23.7±4.4 § 500±99 +5 MM staurosporine (6) 27.5±5.2 § 522±88 +3 mM pyruvate (5) 11.4±4.6" 404±50 Granulation tissue forming in tissue chambers of nondiabetic rats was treated for 10 d with 5 or 30 mM D-glucose supplemented with staurosporine (an inhibitor of protein kinase C), monoolein (an inhibitor of DAG, metabolism), TPA (a phorbol ester activator of protein kinase C), OAG (a membrane-permeable DAG analogue) or pyruvate. Granulation tissue was then harvested and its sorbitol and myo-inositol content determined as described in Methods. Results are shown as the mean±SD of sorbitol and myo-inositol content expressed as nanomoles per gram wet weight of tissue. * No. of animals in parentheses. * Significantly different from 5 mM glucose at P < 0.05. § Significantly different from 5 mM glucose at P < 0.001.
Significantly different from 30 mM glucose control at P < 0.005. pharmacological manipulations described above. Glucose (30 min) caused a 13-fold increase in sorbitol levels (P < 0.001) which was reduced by 50% by 3 mM pyruvate. Treatment of granulation tissue with staurosporine, monoolein, and oleic acid had no effect on sorbitol content (Table II) . Sorbitol levels were slightly elevated in tissues exposed to TPA and DAG.
Discussion
Previous work has established that periodic instillation of high concentrations of glucose into skin chambers induces functional abnormalities in the granulation tissue microvasculature in these chambers, including increased albumin clearance and increased blood flow (16) . This study confirms these findings and establishes that high glucose concentrations also induce accumulation ofDAG in skin chamber granulation tissue. The elevated levels of DAG are consistent with evidence of elevation of DAG levels and ofincreased de novo synthesis of DAG in a variety oftissues exposed to elevated glucose levels in vitro (6) (7) (8) (9) (10) as well as in the heart, retina, and kidney ofdiabetic rats (12, 14, 15) .
De novo synthesis of DAG from dihydroxyacetone phosphate (DHAP) may occur by two pathways. One involves direct acylation of DHAP followed by reduction at carbon two (by NADPH). The resulting lysophosphatidic acid is then further acylated to form phosphatidic acid which is then dephosphorylated to yield DAG. The other involves reduction of DHAP to glycerol-3-phosphate (by NADH) which is then acylated to form lysophosphatidic acid, etc., as in the first pathway. The latter pathway would be favored by increased metabolism of glucose via the sorbitol pathway which has been shown in the lens to increase the NADH:NAD' ratio more than the NADPH:NADP+ ratio (29) .
The likelihood that the elevated levels of DAG in the present experiments reflect increased de novo synthesis of DAG is suggested by evidence that in granulation tissue incubated in 50 mM vs. 5 mM glucose in vitro, triose phosphate levels are significantly increased (29a). This increase in triose phosphate levels, like the increase in DAG levels in the present experiments, is completely prevented by the addition of pyruvate.
While the biochemical mechanism(s) whereby exogenous pyruvate prevents the glucose-induced rise in DAG is not completely established, its effects appear to be linked to normalization of the NAD+:NADH ratio which is decreased by accelerated oxidation of sorbitol to fructose in tissues exposed to high glucose levels. Exogenous pyruvate has also been shown to prevent glucose-induced rises in triose phosphates in red cells, presumably by accelerating oxidation of glyceraldehyde-3-phosphate to glycerate-1,3-biphosphate (30) . The latter reaction requires NAD' which is generated during reduction of pyruvate to lactate. Because the triose phosphates (fructose diphosphate, DHAP, and glyceraldehyde-3-phosphate) are in equilibrium, exogenous pyruvate reduces triose phosphate levels by stimulating their catabolism. The oxidation of NADH to NAD' by pyruvate also decreases the availability of NADH required for reduction of DHAP to glycerol-3-phosphate.
The likelihood that NADH is increased in granulation tissue exposed to elevated glucose levels is also supported by studies of Kawamura et al. (29a) demonstrating increases in the ratio of lactate/pyruvate and fructose/sorbitol. Thus the effects of exogenous pyruvate on DAG synthesis are twofold: (a) it reduces substrate levels (DHAP), and (b) it reduces the availability ofthe co-factor (NADH) needed for reduction ofDHAP to glycerol-3-phosphate. The -50% reduction in tissue sorbitol levels by pyruvate also is consistent with a pyruvate-induced increase in the NAD+:NADH ratio, i.e., the increased availability of NAD+ would stimulate oxidation of sorbitol to fructose which requires NAD+ as the hydrogen receptor. These observations suggest that the biochemical mechanism by which exogenous pyruvate prevents glucose-induced increases in vascular albumin permeation and blood flow may be mediated by normalization of the NAD+:NADH ratio and inhibition of de novo DAG synthesis.
Thus, the glucose-induced increase in DAG levels and its prevention by pyruvate in the present experiments are consistent with increased de novo synthesis of DAG and with the hypothesis that increased DAG levels and associated changes in PKC activity may modulate glucose-induced vascular functional changes. This hypothesis receives further support from the observations that (a) a pharmacological inhibitor ofprotein kinase C (staurosporine) greatly attenuates the glucose-induced rise in microvascular albumin permeation; (b) pharmacological activation ofprotein kinase C with the phorbol ester TPA at physiological glucose levels mimics the effects of elevated glucose levels to increase microvascular albumin clearance and blood flow; (c) pharmacological inhibition ofthe catabolism of endogenous DAG by the DAG kinase inhibitor MOG at physiological glucose concentrations also mimics glucose-induced increases in albumin clearance and blood flow; and (d) prevention of the glucose-induced rise in DAG accumulation with pharmacological concentrations of pyruvate also prevenitsglucose-induced rises in microvascular albumin clearance and blood flow.
It is important to note that periodic instillation of agents into the skin chambers induces only a transient rise in the concentration of the agent which may nonetheless have longerlived effects. Elevated concentrations of glucose instilled into the chambers, for example, are known to be cleared from the chambers with a half-time of 1 h (16). The clearance of pharmacological agents also may occur fairly rapidly, and this likely accounts for the requirement for instillation of higher concentrations of such agents than employed for in vitro biochemical experiments. Accumulation of endogenous DAG induced by MOG is also likely transient, perhaps accounting for the inability to observe a MOG-induced rise in DAG levels, but may induce much longer-lived effects, such as activation and membrane association of protein kinase C or phosphorylation of protein kinase C substrates.
It is of interest that microvascular albumin clearance and blood flow are affected differently by pharmacological interventions directed at the modulation of protein kinase C activity. TPA, for example, induced a rise in albumin clearance essentially identical to that observed with 30 mM glucose, but the TPA-induced rise in blood flow was only about half that induced by 30 mM glucose. Similarly, staurosporine completely prevented the rise in albumin clearance induced by 30 mM glucose or by MOG but had essentially no effect on the rise in blood flow induced by these agents. In addition, instillation of 30 mM glucose into skin chambers for only 2 d induced a rise in blood flow, whereas tissue diacylglycerol content and microvascular albumin permeability were unaffected at that time. After 10 d of instillation, both tissue diacylglycerol content and microvascular albumin permeability rose by about threefold, but there was no further rise in blood flow. These observations suggest that changes in albumin clearance may be much more strongly regulated by protein kinase C than changes in blood flow. DAG accumulation may participate in the regulation of blood flow either through PKC activation or through non-protein kinase C-dependent mechanisms (31) (32) (33) (34) , such as alteration in membrane physical properties (35, 36) or modulation of Na'-K+-ATPase activity (37, 38) . Alternative explanations for the discrepancy in the effects of pharmacologic modulators ofDAG levels and protein kinase C activity must also be considered. It is likely that the increase in microvascular albumin clearance reflects alterations in albumin permeation across venular endothelium whereas increased blood flow reflects vasodilation of resistance arterioles. Thus the differential effects of pharmacological agents on blood flow and albumin clearance may be related to differences in local concentrations of drugs in and around the relatively thick-walled arterioles versus thin walled capillaries and venules and/or differences in permeation of these drugs into arteriolar smooth muscle cells versus capillary and venular endothelial cells.
It is also possible that the discordant effects of pharmacologic modulators ofDAG levels and ofprotein kinase C activity on blood flow and microvascular albumin permeability in this model might reflect the participation of distinct isoenzymes of protein kinase C in the regulation of these parameters (1 1). In addition, both TPA (33) and staurosporine (39) have been reported to exert some biologic actions that are not mediated by interaction with protein kinase C.
In any case, the present studies attest to a potentially important role for glucose-induced increased de novo synthesis of DAG and activation of protein kinase C in mediating glucoseinduced vascular functional changes. Although a similar role for alterations in DAG levels and protein kinase C activity in the pathogenesis of other complications such as diabetic neuropathy seems plausible, evidence linking changes in DAG levels, protein kinase C activity, and associated changes in myoinositol levels and Na'-K+-ATPase activity is either lacking or controversial (40) (41) (42) .
It is ofinterest that a role for protein kinase C similar to that suggested here in regulation of the permeability of endothelial cell layers to albumin has recently been proposed by others on the basis of findings with confluent monolayer cultures of bovine pulmonary artery endothelial cells (43). In that system, TPA increased protein kinase C activity and transepithelial flux of 1251-albumin, and this effect was blocked by pharmacologic inhibitors of protein kinase C. It may be that protein kinase C will prove to play a general role in the regulation ofthe permeability of endothelial cell layers to macromolecules.
In conclusion, our study provides new evidence for a link between glucose-induced increased DAG levels, activation of protein kinase C, and microvascular functional changes in granulation tissue. These microvascular changes correspond to those observed in tissues of human diabetics. Our findings support the hypothesis that increased levels ofDAG and associated changes in protein kinase C activity may participate in the cascade of biochemical imbalances that initiate the late vascular complications of diabetes.
